In July, Cloudbreak Therapeutics, a portfolio company of Efung Capital, successfully landed on the Hong Kong Stock Exchange. Oryzogen and Biotyx Medical became the first two companies to pass the IPO review under the Fifth Set of Standards on the STAR Market, while TnMab became the first company to have its IPO application accepted under the same standard since its restart.
While continuing to gain momentum in the biopharmaceutical sector, other Efung Capital portfolio companies also delivered outstanding performance.
01 Portfolio Company Listing and Financing Progress
Cloudbreak Therapeutics
First International Ophthalmic Innovative Drug Stock in Hong Kong! Cloudbreak Therapeutics Successfully Lists on HKEX
On July 3, Cloudbreak Therapeutics rang the bell for its listing on the Main Board of the Hong Kong Stock Exchange (Stock Code: 02592.HK) with an issue price of HK10.10pershare.TheIPOachievedamarketcapitalizationofHK8.473 billion and raised net proceeds of approximately HK$522 million. This not only marks the successful debut of an innovative ophthalmic drug company on the capital stage but also sounds a bell of hope for hundreds of millions of patients suffering from ophthalmic diseases worldwide.
Oryzogen
Biotyx Medical
One IPO Reviewed, One Approved – The Second Company Under the Restarted Fifth Set of Standards!
On July 18, Biotyx Medical's STAR Market IPO application was approved for review by the Shanghai Stock Exchange's Listing Committee. This marked the second company to pass the review under the restarted Fifth Set of Standards for STAR Market IPOs.
TnMab
TnMab Becomes the First Company to Have Its IPO Application Accepted Under the Restarted Fifth Set of Standards on the STAR Market
On July 31, the Shanghai Stock Exchange accepted TnMab's STAR Market IPO application, making it the first company to have its application accepted following the restart of the Fifth Set of Standards on the STAR Market.
Zhongmou Medical
Zhongmou Medical Completes Tens of Millions of RMB in New Financing Round
On July 28, Wuhan, China – Zhongmou Medical, a global clinical-stage innovative ophthalmic gene therapy company, announced the signing of a new financing agreement for tens of millions of RMB. The lead investor and follow-on investors in this round are all renowned domestic investment institutions, with additional investors still in negotiations, suggesting that the scale of this financing round is expected to expand further. The funds will be primarily used to accelerate global multi-center clinical trials for the core product ZM-02 and subsequent pipeline development, further consolidating the company's leading position in the ophthalmic gene therapy field.
Meichuang Medical
*Suzhou Meichuang Medical Technology Co., Ltd. Completes Approximately RMB 200 Million Series A+ Financing*
Recently, Meichuang Medical announced the completion of approximately RMB 200 million in Series A+ financing. This round was jointly invested by several renowned institutions, including Suzhou Chuangtou, Paradise Silicon Valley, Guanghua Wutong, and Medpark. Following the over RMB 100 million investment from Sequoia China, Efung Capital, Industrial Securities Capital, and QingSong Capital in January 2025, Meichuang Medical has accumulated over RMB 200 million in financing within six months, further reflecting the capital market's continued confidence in the company's industry prospects and development potential.
02 Portfolio Company Clinical and Commercialization Updates
Century Kangtai
World's First, China's First – Century Kangtai Launches Multi-Level Depth-of-Field Extended EDOF Intraocular Lens!
On July 11, at Booth A111 during the 25th Chinese Society of Cataract and Refractive Surgery Annual Meeting (CSCRS 2025), Century Kangtai celebrated a shining moment with the launch of the world's first multi-level depth-of-field extended intraocular lens and China's first EDOF innovative device.
Liangshian® Trifocal Plus Ignites Academic Enthusiasm!
Recently, at CSCRS 2025, Century Kangtai's "Crystal Bright Wisdom – A New Chapter in Vision" series of academic activities drew significant industry attention. Among them, two core events – the "Huaguang Spectrum – A New Vision" Trifocal Symposium and the "Trifocal Wisdom Hall" – brought together 15 top ophthalmic experts to share in-depth insights into the innovative technology and clinical practice wisdom of the new-generation Liangshian® Trifocal Plus Intraocular Lens.
Yingmingda
Small-Probe Endoscopic Ultrasound Installed at Cangzhou Integrated Traditional and Western Medicine Hospital and Two Tier-A Hospitals in Guizhou
Recently, Yingmingda's "Neptune" small-probe endoscopic ultrasound system was successfully installed at the Endoscopy Center of Cangzhou Integrated Traditional and Western Medicine Hospital. The introduction of this advanced device has greatly enriched the department's diagnostic and treatment capabilities, enabling physicians to more adeptly handle complex and difficult digestive system diseases, thereby significantly improving diagnostic efficiency and success rates.
Two major regional medical centers in Guizhou – the First People's Hospital of Zunyi and the People's Hospital of Anshun – respectively introduced Yingmingda's "Uranus" and "Gemini" small-probe endoscopic ultrasound systems, leveraging innovative technology to empower precision diagnosis and treatment, allowing residents to access high-quality medical services close to home.
Meizhong Shuanghe
Meizhong Shuanghe's Peripheral Balloon Wins Bid in Hebei's Interprovincial Alliance Centralized Volume-Based Procurement of Vascular Interventional Medical Consumables
Recently, Meizhong Shuanghe's peripheral balloon won the bid in Hebei's Interprovincial Alliance Centralized Volume-Based Procurement of Vascular Interventional Medical Consumables.
Weimai Medical
Weimai Medical Undertakes National Key R&D Program, Leading the Charge in Core Force Interaction Technology for Interventional Robots
Recently, Weimai Medical participated as a core force in the "Intelligent Robot" special project of the National Key R&D Program – the "Surgical Robot Force Perception and Force Feedback" project. This marks authoritative recognition from the highest-level national research program of Weimai Medical's innovative strength and technological responsibility in the field of interventional surgical robots, deeply integrating into the national strategic layout to overcome "bottleneck" technologies in high-end medical equipment.
Interventional Robot Presents a "Intelligent Manufacturing in China" Card to the World
On July 24-25, the plenary session of the Boao Forum for Asia Global Health Forum 2025 Beijing Conference was held. Weimai Medical, as an outstanding representative of medical robotics companies, was invited to exhibit its We Robot DSA interventional robot, showcasing the contemporary connotation of "Intelligent Manufacturing in China" with its hardcore technological strength.
TnMab
*Featured in Top International Journal Nature Medicine (IF=50.0)*
On July 8, the Phase III clinical trial results of TnMab's globally first anti-tetanus toxin monoclonal antibody new drug – Stotaximab Injection (Brand name: Xintituo) – were published in the top international journal Nature Medicine (IF=50.0).
Haipuluos
Haipuluos Achieves Perfect Score in EMQN DNA Sequencing-NGS!
Recently, the European Molecular Genetics Quality Network (EMQN) announced the results of its 2024 DNA SEQUENCING-NGS (Somatic SNVs and indels + matched germline sample) external quality assessment. Haipuluos passed with a perfect score, representing comprehensive recognition by EMQN of Haipuluos' laboratory technical management capabilities, meaning that Haipuluos' diagnostic quality and standards consistently remain at the highest international level, earning recognition from international authoritative institutions.
Kasier Bio
Globalization Strategy Takes Root – US and Japan Facilities Commence Production Simultaneously!
Amid the current wave of globalization and the accelerating restructuring of the CDMO industry landscape, Kasier Bio has made a "double-barreled" move – completing a strategic controlling stake in NPS, a company under the Japanese PSS Group with a 40-year history in CDMO. Kasier Bio officially took over Japan NPS and its management rights starting July 1. Simultaneously, its US consumables production base commenced operations. This strategic layout not only marks the deep advancement of Kasier Bio's globalization strategy but also, with a "technology + capacity" dual-engine approach, injects certainty into the global pharmaceutical industry chain, reshapes the industry value landscape, and fully opens a new chapter of "dual-core driven" global supply chains.
Beimei Pharma
Beimei Pharma Receives Clinical Trial Application Acceptance Notification for Dermatology Product TWYNEO® (Tretinoin and Benzoyl Peroxide Cream)
On July 22, Beimei Pharma announced that TWYNEO® (Tretinoin and Benzoyl Peroxide Cream) had received the Drug Registration Clinical Trial Application Acceptance Notification from the National Medical Products Administration (NMPA).
Keruichi
Keruichi's Ruiyuan® DiaSphere® Embolic Microspheres' Pre-Market RCT Study Published in Authoritative Journal, Ushering in a New Era of Evidence-Based Embolization Therapy
Recently, Keruichi Medical's independently developed Ruiyuan® DiaSphere® Embolic Microspheres achieved another milestone – the results of its pre-market randomized controlled trial (RCT) were published online in an authoritative journal. As the first embolic microsphere in China to conduct a pre-market RCT clinical study, Ruiyuan® DiaSphere® validates the product's safety and efficacy using the gold standard of evidence-based medicine, filling a gap in pre-market RCT research for high-end medical devices in the field of embolization intervention in China and providing sufficient evidence-based support for its clinical practice.
Xuanyu Medical
Multiple Hospitals Conduct First Batch of Xuanyu RhythPulse® PFA Procedures
Recently, the Cardiology Department team at the First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital) successfully performed the first batch of procedures in China using the domestic innovative device – Xuanyu RhythPulse® Pulsed Field Ablation (PFA) system – employing its unique "large-loop mapping, small-loop ablation" strategy to deliver precise, efficient "heart battles" for two atrial fibrillation patients.
The Cardiology Department at the Shanghai Sixth People's Hospital Lin-gang Campus, fully prepared and closely coordinated, conducted the first batch of Xuanyu RhythPulse® cardiac PFA procedures in China.
The team led by Professor Li Ruogu at the Cardiology Department of Shanghai Chest Hospital successfully completed one of the first batch of domestic Xuanyu Medical RhythPulse® PFA procedures in China.
Dr. Bai Song, Director of the Cardiology Department at Xuyi County People's Hospital, successfully used the Xuanyu Medical RhythPulse® PFA catheter to perform a one-stop procedure combining pulsed field ablation for an atrial fibrillation patient with left atrial appendage closure – one of the first batch of RhythPulse PFA procedures in China.
CAFS 2025 Xuanyu Medical PFA System Launch Conference Successfully Held
Recently, during the 23rd China Atrial Fibrillation Symposium (CAFS 2025), the launch conference for Xuanyu Medical's ShineRhythm® & RhythPulse® Cardiac Pulsed Field Ablation System was successfully held in Dalian, China.
Norling Bio
Electrochemical Catalysis NO Device Aids Postoperative Management of Adult Congenital Heart Disease
Recently, the Cardiothoracic Surgery Department team at Peking University International Hospital published a clinical research paper titled "Innovative nitric oxide delivery technology for postoperative pulmonary hypertension in congenital heart disease patients: a clinical trial" in the journal BMC Cardiovascular Disorders (CAS SCI Region 3), using Norling Bio's electrochemical catalysis nitric oxide therapy device (INOwill N200) to treat adult congenital heart disease-associated pulmonary arterial hypertension (CHD-PAH).
Hannuo Medical
Hannuo Medical Shines at APELSO 2025
From July 10 to 12, the 7th Asia-Pacific Extracorporeal Life Support Organization Annual Meeting (APELSO 2025), co-hosted by the Chinese Society of Biomedical Engineering, the Extracorporeal Circulation Branch of the Chinese Society of Biomedical Engineering, and APELSO, was held in Beijing. Leveraging this authoritative international academic platform, Hannuo Medical systematically showcased its significant progress in product innovation to experts, scholars, and industry peers from the Asia-Pacific region, including: continuous upgrades in device performance – through improved hemodynamic management precision and extended stable device operation time; enhanced clinical convenience and safety – relying on intelligent human-machine interfaces and comprehensive monitoring systems; and ongoing efforts and breakthrough improvements in portable transport solutions.
Lifemotion® ECMO Centrifugal Pump Recognized by International Authority
Recently, research results published in the international authoritative journal ASAIO Journal under the title "Hemolysis in a Novel Centrifugal Blood Pump With Low Priming Volume: In Vitro Comparative Study Using Human Blood and Numerical Analysis" scientifically validated the issue. The study showed that Hannuo Medical's Lifemotion® centrifugal pump not only reduces the pump's size but also lowers the area of high shear stress within the pump, demonstrating excellent hemodynamic performance and a lower risk of hemolysis compared to similar blood pumps.
Kaituo Biotech
Kaituo Biotech Founder Appointed as Entrepreneurship Mentor at Suzhou Biopharma Branch Center, Leveraging CRDMO Platform to Pool Talent and Empower the Ecosystem
Recently, the BioMatch Overseas Talent Special event, hosted by the National University Biomedical Technology Transfer and Transformation Center (Suzhou, Jiangsu) (referred to as "Suzhou Biopharma Branch Center"), was held in Suzhou Industrial Park. Dr. Ren Keyun, General Manager of Kaituo Biotech, was invited to be appointed as an "Entrepreneurship Mentor" at Suzhou Biopharma Branch Center, forming a "think tank" with experts from top institutions such as Hong Kong Polytechnic University and NUSRI to provide precise guidance for the transformation of biopharmaceutical achievements.
Cabaletta Bio (Xunlu Bio)
Cabaletta Bio's Equecabtagene Autoleucel (Fucaso) Receives Orphan Drug Designation from South Korea's MFDS
On July 9, Cabaletta Bio announced that South Korea's Ministry of Food and Drug Safety (MFDS) had granted Orphan Drug Designation (ODD) to its independently developed BCMA-targeted CAR-T cell therapy product Equecabtagene Autoleucel (Fucaso) for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have progressed after at least three prior lines of therapy (including at least one proteasome inhibitor and one immunomodulatory agent).
Tianqin Bio
Co-building a One-Stop New Drug R&D Platform from Target to IND
Recently, Tianqin Bio and Rui Zhi Pharmaceutical Technology Co., Ltd. officially signed a strategic cooperation agreement. This collaboration aims to deeply integrate the core strengths of both parties in the innovative drug R&D industry chain, jointly creating a one-stop service platform covering the entire process "from target discovery to IND," providing more efficient and professional solutions for global pharmaceutical companies.
Senmai Medical
Pioneering Global Collaboration to Build a New Blueprint for Intelligent Drug Delivery
Recently, the globally renowned pharmaceutical event CPHI China 2025 concluded successfully. Senmai Medical Technology and international pharmaceutical packaging brand Nanjing Batafulai signed a strategic cooperation agreement, jointly embarking on a new journey of global innovation and industrial application of drug delivery devices. This collaboration focuses on the development of specialty packaging materials and secondary pharmaceutical packaging materials, aiming to provide better overall solutions for customers, achieve drug-device integration, and bring new breakthroughs to the healthcare industry.
Chipscreen Biosciences
Milestone in First-Line DLBCL Treatment! Chidamide DEB Study Final Topline Analysis Achieves EFS Primary Endpoint
Recently, the pivotal Phase III clinical trial (DEB Study) of Chipscreen Biosciences' globally first-in-class optimal drug Chidamide combined with existing first-line therapy and followed by monotherapy maintenance for diffuse large B-cell lymphoma (DLBCL) completed its final topline analysis. Results showed that the event-free survival (EFS) in the experimental group was significantly superior to the control group, achieving the study's primary endpoint.
Ascentage Pharma
*China's First Domestic Original Bcl-2 Inhibitor Lishengto® (Lisatoclax) Issues First Batches of Prescriptions*
On July 25, Ascentage Pharma announced that the first batches of prescriptions for China's first domestic original Bcl-2 inhibitor Lishengto® (Generic name: Lisatoclax; R&D code: APG-2575) were issued in multiple locations across the country, with drug supply commencing in various provinces and cities.
Ascentage Pharma Partners with Leading Pharmaceutical Distribution Companies to Comprehensively Advance Lishengto® Commercialization
Recently, Ascentage Pharma announced that it has signed cooperation agreements with Sinopharm Holding Co., Ltd. ("Sinopharm Holding"), Shanghai Pharmaceutical Holding Co., Ltd. ("Shanghai Pharmaceutical Holding"), and Huarun Tianjin Pharmaceutical Co., Ltd. ("Huarun Tianjin"). This collaboration aims to leverage the respective strengths of both parties in R&D innovation, market development, and channel management to jointly promote the commercialization of China's first approved original Bcl-2 inhibitor Lishengto® (Generic name: Lisatoclax).
Oryzogen
Leading International Hepatology Journal Gut Publishes Commentary on the Clinical Significance of Oryzogen's Aofumin® for Albumin Therapy
Recently, Gut (Impact Factor 25.8), the official journal of the British Society of Gastroenterology, published a special commentary co-authored by Professor Rajiv Jalan from University College London and Professor Paolo Caraceni from the University of Bologna, providing an in-depth analysis of the Phase II clinical study of rice endosperm-expressed recombinant human albumin (Aofumin®) developed by Chinese researchers. Entitled "New Frontier in Albumin Replacement Therapy," the commentary suggests that this innovative therapy may reshape the landscape of albumin treatment for patients with cirrhosis.
Cloudbreak Therapeutics
*Positive Topline Results from Phase II Clinical Trial of CBT-004 for Treatment of Vascularized Pinguecula*
Recently, Cloudbreak Therapeutics announced positive topline results from its Phase II clinical trial evaluating CBT-004 Ophthalmic Solution for the treatment of vascularized pinguecula and associated conjunctival hyperemia.
Key Results of Phase II Clinical Trial:
Primary Endpoint Met: Central reading center assessment via digital imaging showed that on Day 28, both tested concentrations of CBT-004 demonstrated statistically significant improvement in conjunctival hyperemia compared to the vehicle control group.
Rapid Onset and Durable Effect: The highest tested concentration of CBT-004 showed significant improvement as early as Day 7, with benefits lasting throughout the 28-day treatment period.
Significant Symptom Relief: Both concentrations of CBT-004 showed statistically significant improvement over vehicle in five patient-reported common symptoms (including burning/stinging, itching, foreign body sensation, eye discomfort, and pain).
Excellent Safety Profile: No treatment-related adverse events were reported. Most adverse events were mild to moderate. No clinically significant changes in visual acuity or intraocular pressure were reported.
Xuanzhu Biopharma
*First National Shipment of Pyrociclib Tablets (Xuanyuening®) Ushers in a New Treatment Paradigm for Advanced HR+/HER2- Breast Cancer*
Recently, the first batch of commercial products of Xuanzhu Biopharma's independently developed Class 1 innovative drug Pyrociclib Tablets (Xuanyuening®) successfully completed production packaging and quality release at Asymchem Laboratories, marking the official entry of this strategic innovative drug, included in the "National 13th Five-Year Major New Drug Creation Science and Technology Major Special Project," into the commercial supply phase. As a major breakthrough in breast cancer treatment in China, this drug will provide a better treatment option for patients with HR+/HER2- advanced breast cancer.
*First Batches of Pyrociclib Tablets (Xuanyuening®) Prescriptions Filled, Successfully Filling the Gap in Late-Line Monotherapy for Advanced HR+/HER2- Breast Cancer in China*
Recently, Xuanzhu Biopharma's Class 1 innovative drug Pyrociclib Tablets (Xuanyuening®), as the first and currently only CDK4/6 inhibitor for late-line monotherapy of HR+/HER2- breast cancer in China, has completed its first national drug supply and had its first batches of prescriptions issued in multiple hospitals for clinical use. This marks the official entry of advanced breast cancer treatment in China into a new era of "high efficacy, low toxicity, monotherapy breakthrough," providing entirely new treatment options for breast cancer patients.
First Subject Enrolled in Phase III Clinical Study of New-Generation PPI Anaprazole Sodium Enteric-Coated Tablets for Reflux Esophagitis
On July 30, the first subject was enrolled in the Phase III clinical study (CTR20252165) for the treatment of reflux esophagitis with Xuanzhu Biopharma's independently developed Class 1 new drug – Anaprazole Sodium Enteric-Coated Tablets – at the Second Affiliated Hospital of Wenzhou Medical University. This marks a significant milestone in the R&D progress of Anaprazole Sodium, bringing the goal of providing better treatment options for the large population of reflux esophagitis patients in China one step closer.
Frontier Biotech
*Research Results of Aikening® Once-Every-4-Weeks Dosing Combined with Dolutegravir Presented at the 13th IAS Conference on HIV Science*
On July 13, the 13th IAS Conference on HIV Science (IAS 2025) was held in Kigali, Rwanda. Frontier Biotech presented two innovative research results on Aikening® (Generic name: Albuvirtide) once-every-4-weeks dosing combined with dolutegravir, showcasing the "Chinese solution" for long-acting HIV treatment to the world in the form of poster presentations.
03 Portfolio Company New Drug and Device Approvals
Oryzogen
World's First "Rice-Sourced Hematopoiesis" Technology! Oryzogen's Plant-Derived Recombinant Human Serum Albumin Injection Approved for Marketing
On July 18, the Plant-Derived Recombinant Human Albumin Injection, developed by Wuhan Oryzogen Biotechnology Co., Ltd. using "rice-sourced hematopoiesis" technology, was officially approved for marketing for the treatment of hypoalbuminemia (≤30g/L) in liver cirrhosis. This is the first Class 1 innovative drug produced using a rice endosperm cell bioreactor in China and internationally. Its approval for clinical research was a milestone event for plant bioreactor research and utilization in China, providing a new pathway for protein drug production in the country.
Biotyx Medical
First Domestically Produced Peripheral IVUS Catheter Approved
On July 4, Biotyx's TrueVision18 Peripheral IVUS (Intravascular Ultrasound) catheter officially received Class III medical device registration approval from the NMPA, breaking the import monopoly and marking a breakthrough in precision peripheral vascular intervention in China.
Tingsheng Technology
FDA Clearance Secured | Tingsheng Technology Begins Global Journey for Domestic Intracardiac Ultrasound
Recently, Tingsheng Technology's independently developed Intracardiac Echocardiography (ICE) diagnostic system successfully received FDA clearance (K-number: K250913). This breakthrough not only marks the entry of China's high-end cardiac interventional imaging equipment into the world's most advanced medical market but also signifies a leapfrog development in this field from "complete reliance on imports" to "domestic reverse export," establishing a new milestone for the internationalization of China's medical device industry.
Westlake Omics
Westlake Omics Receives Approval for World's First Low-Resolution Clinical Proteomics Diagnostic Product
Recently, Westlake Omics received approval for the world's first low-resolution clinical proteomics diagnostic product, independently developed by the company.
Xuanyu Medical
Cardiac Pulsed Field Ablation System Launched
Recently, Xuanyu Medical's RhythPulse®-PFA system was launched. It is the first PFA system approved in China that integrates multi-channel, large-focal, and targeted ablation capabilities, primarily used for the treatment of drug-refractory, recurrent atrial fibrillation and other tachyarrhythmias.
Ascentage Pharma
*First in China! Ascentage Pharma's Self-Developed Bcl-2 Inhibitor Officially Approved for Marketing*
On July 10, Ascentage Pharma officially announced that its self-developed novel selective Bcl-2 inhibitor APG-2575 (Generic name: Lisatoclax) had successfully received conditional marketing approval from China's NMPA for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have received at least one prior systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor.
*China's First Original Self-Developed Bcl-2 Inhibitor – Lishengto® (Lisatoclax) Approved for Marketing*
Recently, Lishengto® (Lisatoclax), China's first original self-developed Bcl-2 inhibitor, was approved for marketing. This means that patients with CLL/SLL in China now have a powerful new treatment option, marking a major milestone in China's innovative drug development.
Chipscreen Biosciences
*US IND for Chipscreen Biosciences' Brain-Penetrant Selective Aurora B Inhibitor CS231295 Tablets Approved by FDA*
On July 31, the Clinical Trial Application (IND) for CS231295 Tablets, a next-generation brain-penetrant selective Aurora B inhibitor for the treatment of advanced solid tumors, submitted by Chipscreen Biosciences (USA) Ltd., a wholly-owned subsidiary of Chipscreen Biosciences, was approved by the U.S. FDA.
Biostar Pharma
First Patient Enrolled in Phase III Adjuvant Trial of Utidelone Capsules for Triple-Negative Breast Cancer
On July 14, Biostar Pharma announced that the first patient had been dosed in a Phase III clinical trial (NCT07021261) evaluating "Utidelone Capsules (UTD2) in combination with capecitabine versus capecitabine alone as adjuvant therapy for patients with triple-negative early breast cancer who did not achieve pathological complete response after neoadjuvant therapy."
Lifotronic Technology
Electronic Cysto-ureteroscope Launched
Lifotronic Technology officially launched its Electronic Cysto-ureteroscope. The insertion tube is constructed from a 5-layer composite material, featuring a sapphire lens to reduce device replacement frequency, lower department operating costs, and provide reliable support for high-intensity diagnosis and treatment scenarios.
04 Portfolio Company Honors
Selected for Hao Yue Capital's "Best Innovative Medical Device Companies of the Year"
Selected for Hao Yue Capital's "Best Innovative Pharmaceutical Companies of the Year"
Selected for Securities Times' "2025 High-Growth Enterprises"
Selected for Hubei Intellectual Property Administration's "Second Hubei Province Patent Award – Silver Prize"
Selected for CFS's "2025 Outstanding Medical Technology Innovation Award"
Selected for China Securities Journal's "Golden Bull Technology Innovation Enterprise Award"
Selected for Zero2IPO's "Top 100 Sharp Companies"
Selected for Greatwall Strategy Consultants' "2024 GEI China Unicorn Enterprise List"
Selected for China Optics Valley's "2025 'Gazelle Select' Enterprises"
Selected for the 2025 European Society of Cardiology Congress "Late-Breaking Clinical Trials" Session
Selected as Champion of the 10th "Maker in China" and "Zhejiang Good Project" – 2025 Maker in China Hangzhou Division Biopharma Special
Selected for CFS's "Outstanding Biotech Innovation Leadership Award"
Selected for Zero2IPO's "2024-2025 AI+Healthcare Innovation Leading Enterprise"
Selected for the 2025 World Artificial Intelligence Conference's "2025 Recommended List of Sustainable Innovation Cases in Healthcare"
05 Efung Capital Honors